Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Genmab A/S (GMAB)
NASDAQ:GMAB
Holding GMAB?
Track your performance easily
GMAB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$19.85 - $31.88
Previous CloseN/A
Volume229.76K
Average Volume (3M)1.10M
Market Cap
$13.34B
Enterprise Value$13.14B
Total Cash (Recent Filing)$3.92B
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)19.9
Beta0.57
Next Earnings
Feb 12, 2025EPS Estimate
0.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.04
Shares Outstanding661,871,800
10 Day Avg. Volume1,178,079
30 Day Avg. Volume1,096,337
Standard Deviation0.10
R-Squared0.27
Alpha-0.00747
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.20
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.98
Enterprise Value/Revenue1.81
Enterprise Value/Gross Profit0.81
Enterprise Value/Ebitda2.20
Forecast
1Y Price Target
$43.00Price Target Upside106.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Genmab News
PremiumCompany Announcements
Genmab A/S Expands Share Capital and Warrants
PremiumCompany Announcements
Genmab Increases Capital Through Employee Warrant Exercise
PremiumCompany Announcements
Genmab Discloses Share Transactions by Executives
PremiumCompany Announcements
Genmab A/S Plans Strategic Capital Expansion by 2029Bulls Say, Bears Say
Bulls Say
Drug PerformanceGenmab's partner Janssen announced that RYBREVANT and LAZCLUZE demonstrated a statistically significant overall survival benefit in the Phase 3 MARIPOSA trial.
Financial PerformanceDarzalex sales exceeded consensus estimates, demonstrating strong performance and growth.
Strategic DevelopmentGenmab is well positioned in the biotech sector with a strong balance sheet and a track record of profitability.
Bears Say
Competitive Pressure And Patent IssuesGenmab's Cash Cow Darzalex is under growing pressure from GSK's Blenrep and the 2030 Patent Cliff.
Product Sales And Market PenetrationRisks include slowing DARZALEX sales and failure to obtain DARZALEX label extensions.
Program Termination And Study DecisionsGMAB announced the termination of three early-stage programs and the decision not to initiate a planned Phase III study for Tivdak.
---
Ownership Overview
―
Insiders
1.15% Mutual Funds
<0.01% Other Institutional Investors
98.01% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GMAB FAQ
What was Genmab A/S’s price range in the past 12 months?
Genmab A/S lowest stock price was $19.85 and its highest was $31.88 in the past 12 months.
What is Genmab A/S’s market cap?
Genmab A/S’s market cap is $13.34B.
When is Genmab A/S’s upcoming earnings report date?
Genmab A/S’s upcoming earnings report date is Feb 12, 2025 which is in 25 days.
How were Genmab A/S’s earnings last quarter?
Genmab A/S released its earnings results on Nov 06, 2024. The company reported $0.287 earnings per share for the quarter, missing the consensus estimate of $0.308 by -$0.021.
Is Genmab A/S overvalued?
According to Wall Street analysts Genmab A/S’s price is currently Undervalued.
Does Genmab A/S pay dividends?
Genmab A/S does not currently pay dividends.
What is Genmab A/S’s EPS estimate?
Genmab A/S’s EPS estimate is 0.36.
How many shares outstanding does Genmab A/S have?
Genmab A/S has 661,871,800 shares outstanding.
What happened to Genmab A/S’s price movement after its last earnings report?
Genmab A/S reported an EPS of $0.287 in its last earnings report, missing expectations of $0.308. Following the earnings report the stock price went down -1.846%.
Which hedge fund is a major shareholder of Genmab A/S?
Among the largest hedge funds holding Genmab A/S’s share is Graham Capital Management, L.P.. It holds Genmab A/S’s shares valued at 978K.
---
Genmab Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$43.00 (106.73% Upside)
$43.00 (106.73% Upside)
Blogger Sentiment
Bullish
GMAB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 17.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.64%
12-Months-Change
Fundamentals
Return on Equity
14.67%
Trailing 12-Months
Asset Growth
18.68%
Trailing 12-Months
Company Description
Genmab A/S
Genmab A/S is an international biotech company. It is specialized in creating and developing differentiated antibody therapeutics for the treatment of cancer. The company currently markets DARZALEX monoclonal antibody for the treatment of patients with multiple myeloma and Arzerra monoclonal antibody for the treatment of chronic lymphocytic leukemia.
---
GMAB Company Deck
---
GMAB Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
Genmab demonstrated a strong financial performance in Q1 2024, with significant revenue growth and successful product launches. However, increased operational expenses and ongoing regulatory challenges present potential obstacles.Read More>---
GMAB Stock 12 Month Forecast
Average Price Target
$43.00
▲(106.73% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Regeneron
―
Vertex Pharmaceuticals
―
Incyte
―
Alnylam Pharma
―
Amgen
―
Best Analysts Covering GMAB
1 Year
1 Year Success Rate
2/15 ratings generated profit
1 Year Average Return
-15.24%
assigned a buy rating 2 months ago
Copying Asthika Goonewardene's trades and holding each position for 1 Year would result in 13.33% of your transactions generating a profit, with an average return of -15.24% per trade.
---